Tris Pharma Expands ADHD Portfolio with Acquisition of NextWave Pharmaceuticals

Tris Pharma announced the acquisition of NextWave Pharmaceuticals (NextWave), a wholly owned subsidiary of Pfizer Inc. (Pfizer), including two key Attention Deficit Hyperactivity Disorder (ADHD) treatments. The acquisition further expands Tris’ portfolio of products for the treatment of patients with ADHD. The agreement includes the acquisition of Quillivant XR, the first and only marketed extended-release oral liquid methylphenidate, and QuilliChew ER, the first and only extended-release methylphenidate chewable tablet, both of which are central nervous system (CNS) stimulants approved for the treatment of ADHD.

Please see important safety information for Quillivant XR and QuilliChew ER, including Boxed Warning about Abuse and Dependence, below.

Quillivant XR and QuilliChew ER were co-developed by NextWave and Tris, utilizing Tris’ novel, proprietary LiquiXR ® platform. In 2012, Pfizer acquired NextWave, and Tris continued to manufacture both products for Pfizer, prior to and after US Food and Drug Administration (FDA) approval.

“As co-developer of Quillivant XR and QuilliChew ER, we are excited to bring commercialization of these products in house and expand our ADHD portfolio,” said Ketan Mehta, President and Chief Executive Officer, Tris. “To further support our newest acquisition, Tris is expanding our commercial footprint and building a world class medical affairs group.”

“Our newest acquisition brings us one step closer to realizing our corporate mission, to develop and expand offerings to meet unmet needs for all patients,” said Barry K. Herman, M.D., M.M.M., Tris’ Chief Medical Officer. “With three treatment options for patients with ADHD, Tris now offers a broad, established product portfolio with both stimulant classes in the ADHD space.”

DYANAVEL XR is the first liquid amphetamine for children 6 years and older with ADHD, launched by Tris in 2016.